The advent of chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
Manali Kamdar, MD, on Practical Considerations for Using CAR T-Cells for DLBCL
Default sub title
minute read
by MedPage Today | August 29, 2023
